U.S. Markets open in 4 hrs 43 mins

Sarepta Therapeutics, Inc. (SRPT)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
43.95+0.54 (+1.24%)
At close: 4:00PM EDT
People also watch
CLVSACADJUNOKITEPTCT

Sarepta Therapeutics, Inc.

215 First Street
Suite 415
Cambridge, MA 02142
United States
617-274-4000
http://www.sarepta.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees197

Key Executives

NameTitlePayExercisedAge
Mr. Sandesh Mahatme LL.M.Chief Financial Officer, Chief Bus. Officer and Exec. VP704.13k81.21k52
Mr. David Tyronne Howton Jr.Sr. VP, Gen. Counsel and Corp. Sec.615.34k72k45
Mr. Alexander Bo CumboSr. VP & Chief Commercial Officer478.15k39.34k46
Ms. Shamim RuffSr. VP of Regulatory Affairs and Quality542.55k47.21k57
Dr. Edward M. Kaye M.D., Ph.D.Advisor979.3k1.09M68
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. The company has a strategic alliance with Nationwide Children's Hospital for the advancement of microdystrophin gene therapy program under the research and option agreement, as well as Galgt2 gene therapy program under the license agreement; Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD under the research collaboration agreement; and Charley’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies under the research agreement. It also has a license agreement with the University of Western Australia for treatment of DMD by inducing the skipping of certain exons; collaboration and license agreement with Summit (Oxford) Ltd. for the development of ezutromid, an utrophin modulator which is in phase II clinical trials for the treatment of DMD; and a gene therapy research collaboration with Genethon to develop treatments for Duchenne muscular dystrophy. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Sarepta Therapeutics, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 3. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 4; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.